Aditya Bardia, MD, MPH, Director of Breast Cancer Research, Mass General Cancer Center, Harvard Medical School speaks about ASCO 2021 Highlights in Breast Cancer.
Link to Abstract – OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
https://meetinglibrary.asco.org/record/115571/abstract
Link to Abstract – Significantly different costs of adjuvant chemotherapy regimens in the United States.
https://meetinglibrary.asco.org/record/60336/abstract
Link to Abstract – Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
https://meetinglibrary.asco.org/record/196389/abstract
Link to Abstract – KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
https://meetinglibrary.asco.org/record/165258/abstract
Link to Abstract – Relative risk of hepatotoxicity associated with cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.
https://meetinglibrary.asco.org/record/199969/abstract
Link to Abstract – Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
https://meetinglibrary.asco.org/record/198455/abstract
Link to Abstract – Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).
https://meetinglibrary.asco.org/record/195728/abstract
Link to Abstract – Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).
https://meetinglibrary.asco.org/record/195726/abstract
Link to Abstract – AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
https://meetinglibrary.asco.org/record/198207/abstract
Link to Abstract – Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).